MA71733A - Protéines se liant à nkg2d, cd16 et ceacam5 - Google Patents

Protéines se liant à nkg2d, cd16 et ceacam5

Info

Publication number
MA71733A
MA71733A MA71733A MA71733A MA71733A MA 71733 A MA71733 A MA 71733A MA 71733 A MA71733 A MA 71733A MA 71733 A MA71733 A MA 71733A MA 71733 A MA71733 A MA 71733A
Authority
MA
Morocco
Prior art keywords
ceacam5
nkg2d
proteins binding
proteins
binding
Prior art date
Application number
MA71733A
Other languages
English (en)
Inventor
Asya Grinberg
Laurence FAYADAT-DILMAN
Gregory P. CHANG
Ann F. CHEUNG
Nicolai Wagtmann
Pyae P. HEIN
Amy M. Beebe
Veronica M. JAUN
Souvik CHATTOPADHYAY
Original Assignee
Dragonfly Therapeutics, Inc.
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics, Inc., Merck Sharp & Dohme Llc filed Critical Dragonfly Therapeutics, Inc.
Publication of MA71733A publication Critical patent/MA71733A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA71733A 2022-08-10 2023-08-08 Protéines se liant à nkg2d, cd16 et ceacam5 MA71733A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263396910P 2022-08-10 2022-08-10
PCT/US2023/029676 WO2024035662A2 (fr) 2022-08-10 2023-08-08 Protéines se liant à nkg2d, cd16 et ceacam5
EP23768025.1A EP4569002A2 (fr) 2022-08-10 2023-08-08 Protéines se liant à nkg2d, cd16 et ceacam5

Publications (1)

Publication Number Publication Date
MA71733A true MA71733A (fr) 2025-05-30

Family

ID=87974268

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71733A MA71733A (fr) 2022-08-10 2023-08-08 Protéines se liant à nkg2d, cd16 et ceacam5

Country Status (19)

Country Link
US (1) US20240124607A1 (fr)
EP (1) EP4569002A2 (fr)
JP (1) JP2025527967A (fr)
KR (1) KR20250046323A (fr)
CN (1) CN119923412A (fr)
AR (1) AR130144A1 (fr)
AU (1) AU2023323773A1 (fr)
CA (1) CA3263798A1 (fr)
CL (1) CL2025000343A1 (fr)
CO (1) CO2025001294A2 (fr)
DO (1) DOP2025000023A (fr)
GE (1) GEAP202516697A (fr)
IL (1) IL318770A (fr)
JO (1) JOP20250032A1 (fr)
MA (1) MA71733A (fr)
MX (1) MX2025001591A (fr)
PE (1) PE20250928A1 (fr)
TW (1) TW202417483A (fr)
WO (1) WO2024035662A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116199777B (zh) * 2021-12-01 2025-01-28 北京免疫方舟医药科技有限公司 抗hNKG2D抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2478110B1 (fr) 2009-09-16 2016-01-06 Immunomedics, Inc. Anticorps anti-cea de classe i et leurs utilisations
WO2013054320A1 (fr) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Anticorps dirigés contre la molécule d'adhésion cellulaire associée à l'antigène carcino-embryonnaire (ceacam)
DK3199552T3 (da) 2012-11-20 2020-03-30 Sanofi Sa Anti-ceacam5-antistoffer og anvendelser heraf
WO2015095412A1 (fr) 2013-12-19 2015-06-25 Zhong Wang Anticorps bispécifique comprenant deux fragments de liaison à l'antigène à domaine unique
WO2016134371A2 (fr) 2015-02-20 2016-08-25 Ohio State Innovation Foundation Anticorps bivalent dirigé contre nkg2d et antigènes associés à une tumeur
AU2018219887B2 (en) 2017-02-08 2024-08-15 Dragonfly Therapeutics, LLC Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CA3177692A1 (fr) * 2017-02-27 2018-08-30 Dragonfly Therapeutics, Inc. Proteines de liaison multispecifiques ciblant caix, ano1, mesotheline, trop2, ou claudin-18.2
CA3237846A1 (fr) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Domaines variables d'anticorps ciblant le recepteur nkg2d
AU2020289301B2 (en) * 2019-06-04 2025-07-24 Biotheus Inc. CEACAM5-resistant monoclonal antibody and preparation method thereof and use thereof
US20230257467A1 (en) * 2020-08-05 2023-08-17 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and egfr

Also Published As

Publication number Publication date
TW202417483A (zh) 2024-05-01
WO2024035662A3 (fr) 2024-05-16
AR130144A1 (es) 2024-11-06
GEAP202516697A (en) 2025-05-27
PE20250928A1 (es) 2025-04-02
CN119923412A (zh) 2025-05-02
JOP20250032A1 (ar) 2025-02-06
WO2024035662A2 (fr) 2024-02-15
CA3263798A1 (fr) 2024-02-15
EP4569002A2 (fr) 2025-06-18
AU2023323773A1 (en) 2025-03-27
US20240124607A1 (en) 2024-04-18
KR20250046323A (ko) 2025-04-02
JP2025527967A (ja) 2025-08-26
CO2025001294A2 (es) 2025-02-13
IL318770A (en) 2025-04-01
CL2025000343A1 (es) 2025-06-06
MX2025001591A (es) 2025-03-07
DOP2025000023A (es) 2025-04-15

Similar Documents

Publication Publication Date Title
EP4408896A4 (fr) Protéines liant nkg2d, cd16 et baff-r
EP3795595A4 (fr) Protéine de fusion se liant à la protéine cd47 et utilisation associée
EP3833386A4 (fr) Protéines de liaison multi-spécifiques se liant à her2, nkg2d, et cd16, et méthodes d'utilisation
MA50255A (fr) Protéines de liaison à nkg2d, cd16, et molécule-1 semblable à la lectine de type c (cll-1)
PL4192872T3 (pl) Białka wiążące nkg2d, cd16 i egfr
MA47465A (fr) Protéines fixant le bcma, le nkg2d et le cd16
EA200701211A1 (ru) Полипептиды, которые связываются с br3, и их применение
UY39118A (es) ANTICUERPOS CONTRA SARS-Cov-2 (SARS2, COVID-19)
WO2019236749A3 (fr) Procédés et applications d'identification de protéines
EA201792442A1 (ru) Биспецифические агенты, связывающие простатический специфический мембранный антиген (psma), и их применение
MX2022001049A (es) Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos.
IL285668A (en) Bispecific fusion protein using orthopoxvirus major histocompatibility complex (mhc) class l-like protein (omcp) and tumor-specific binding partner
EA200801621A1 (ru) Антитела, направленные на her-3, и их применение
MA71733A (fr) Protéines se liant à nkg2d, cd16 et ceacam5
AR068347A1 (es) Proteinas de union a antigenos c-fms humanos
MY150400A (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
WO2020128446A3 (fr) Anticorps btla
BR112021023540A2 (pt) Agentes de afinidade
EP4174092A4 (fr) Protéine de liaison multi-spécifique d'un recruteur de cellules immunitaires, préparation et utilisation associées
MA56468A (fr) Protéines de liaison à l'antigène de carcinome 1 à cellules squameuses de l'oesophage anti-new york (ny-eso-1) et leurs procédés d'utilisation
EP3882266A4 (fr) Molécule de liaison spécifique à la protéine lrig-1, et utilisation associée
WO2021226289A3 (fr) Compositions et procédés pour la reprogrammation de tcr au moyen de protéines de fusion spécifiques cd70
PH12022551597A1 (en) ANTI-SIRPa MONOCLONAL ANTIBODIES AND USES THEREOF
MX2020003672A (es) Proteinas de fusion inmunomoduladora.
EP3805265A4 (fr) Anticorps se liant à tie2 et son utilisation